NCT03869294

GS Regimen as the First-line Chemotherapy in Chinese Advanced PC Patients

Gemcitabine Plus S-1 as the First-line Chemotherapy in Chinese Patients With Advanced Pancreatic Cancer

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 96 (actual)
• Sponsor: Zhejiang University · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Gemcitabine plus S-1 (GS) prolonged progression-free survival (PFS) and greatly improved objective response rate (ORR) as well as disease control rate (DCR) of Asian patients with locally advanced and metastatic pancreatic cancer (PC). However, limited data of GS regimen exist on the efficacy and safety in the treatment of Chinese patients with advanced PC. To assess the efficacy and safety of gemcitabine plus S-1 (GS regimen) as the first-line chemotherapy in Chinese patients with advanced PC, we designed this prospective study.

Conditions

• Pancreatic Cancer
• Chemotherapy Effect
• Chemotherapeutic Toxicity

Interventions

Type	Name	Description
DRUG	GS	Gemcitabine plus S-1 (GS) was used to treat advanced pancreatic cancer

Timeline

• Start date: 2014-01-01
• Primary completion: 2017-12-31
• Completion: 2017-12-31
• First posted: 2019-03-11
• Last updated: 2020-03-04

Locations

1 site across 1 country: China